Novo Nordisk Q3 2026 results, published on 4 November 2026, show adjusted operating profit rising 27% at constant exchange rates (CER) to DKK 31,720 million. The Danish drugmaker Novo Nordisk also raised its full-year outlook on continued GLP-1 momentum. The report covers 1 January to 30 September 2026 and centres on the Wegovy pill, the CagriSema pipeline and a change in finance leadership.
Adjusted and reported sales both grew 4% at CER in the quarter to DKK 79,195 million. Growth was driven by GLP-1 volume increases in the US and International Operations, mainly in obesity. Reported operating profit fell 9% at CER to DKK 23,011 million because of DKK 8.7 billion in non-cash impairments tied to ziltivekimab and the manufacturing network. President and CEO Mike Doustdar described a stronger-than-expected third quarter.
Management now expects 2026 adjusted sales growth and adjusted operating profit growth of -2% to +2% at CER. That is an upgrade from the -6% to 0% range given on 4 August 2026. Readers tracking the Novo Nordisk Q3 2026 results should note that the improved outlook is attributed mainly to higher expectations for GLP-1 product sales in both operating units. These statements are forward-looking and carry the risks Novo lists in its report.
Wegovy Pill Drives Obesity Growth in Novo Nordisk Q3 2026 Results
The Wegovy pill generated DKK 5,394 million in Q3 sales, of which US Operations contributed DKK 4,178 million and International Operations DKK 1,216 million. Novo launched the product in the US on 5 January 2026. It reports roughly 3.6 million prescriptions in Q3 and more than 8 million since launch, which it calls the strongest GLP-1 volume launch in the US.
Total obesity sales rose 22% at CER to DKK 26,146 million. Wegovy injectable sales were DKK 20,407 million, down 2% at CER, with US injectable sales falling 13% while International Operations rose 16%. In the US, Novo says the Wegovy franchise holds more than 50% of new patient starts among branded obesity medicines. It estimates the pill’s new-to-brand share at around 80%, a trend that matters across the wider GLP-1 obesity market.
Access and pricing remain central to the Novo Nordisk Q3 2026 results. Self-pay prices for the pill range from USD 149 to 299 per month by dose, and Medicare Part D obesity coverage began through the Bridge programme on 1 July 2026. Around 55,000 active subscriptions were recorded at the end of Q3. Novo also confirmed that, effective 1 January 2027, it will cut US list prices to USD 675 for several Wegovy and Ozempic presentations.
Key Brand Sales, Q3 and 9M 2026 (Adjusted, DKK million)
| Product / Segment | Q3 2026 Sales | Q3 Growth at CER | 9M 2026 Sales | 9M Growth at CER |
|---|---|---|---|---|
| Wegovy injectable | 20,407 | (2%) | 58,126 | 4% |
| Wegovy pill | 5,394 | N/A | 10,868 | N/A |
| Ozempic injectable | 29,706 | (5%) | 88,906 | (3%) |
| Ozempic pill / Rybelsus | 4,938 | (10%) | 14,738 | (10%) |
| Total obesity | 26,146 | 22% | 70,210 | 20% |
| Total diabetes | 47,545 | (5%) | 142,910 | (5%) |
| Total insulin | 12,265 | 2% | 36,851 | (4%) |
| Blood & endocrine disorders | 5,504 | 15% | 14,626 | 6% |
Diabetes was softer. Total diabetes sales fell 5% at CER to DKK 47,545 million, with US GLP-1 diabetes sales down 10% on lower volumes and wholesaler inventory movements. Ozempic pill, made available nationwide in the US on 4 May, shows new-to-brand prescriptions up around 100% against pre-launch Rybelsus levels. An FDA decision on the 25 mg dose is expected in Q4 2026. Region EUCAN sales rose 18% in the quarter, while APAC fell 7% and Region China fell 5%.
Financial Performance in Novo Nordisk Q3 2026 Results: Margins, Impairments and Cash Flow
Adjusted gross margin reached 82.1% in Q3 against 76.1% a year earlier. Novo credits savings from the company-wide transformation announced in Q3 2025, productivity gains and favourable currency. Sales and distribution costs fell 9% at CER, while adjusted research and development costs fell 1%. The year-earlier comparison also benefited from roughly DKK 9 billion of transformation costs booked in Q3 2025.
Profitability in the Novo Nordisk Q3 2026 results was mixed. Net profit declined 16% to DKK 16,740 million and diluted earnings per share fell to DKK 3.79, reflecting the impairments and a net financial loss of DKK 1,577 million. Over nine months, reported sales rose 13% at CER to DKK 254,506 million, but that figure includes a DKK 26.8 billion non-cash reversal of 340B rebate provisions recorded in Q1 2026. Excluding it, nine-month adjusted sales grew 2% at CER to DKK 227,746 million.
Financial Highlights, Q3 and 9M 2026 (DKK million unless stated)
| Metric | Q3 2026 | Q3 Growth in DKK | Q3 Growth at CER | 9M 2026 | 9M Growth in DKK | 9M Growth at CER |
|---|---|---|---|---|---|---|
| Net sales (reported) | 79,195 | 6% | 4% | 254,506 | 11% | 13% |
| Adjusted net sales | 79,195 | 6% | 4% | 227,746 | 0% | 2% |
| Operating profit (reported) | 23,011 | (3%) | (9%) | 109,690 | 14% | 18% |
| Adjusted operating profit | 31,720 | 34% | 27% | 97,967 | 5% | 8% |
| Adjusted operating margin | 40.1% | N/A | N/A | 43.0% | N/A | N/A |
| Net profit | 16,740 | (16%) | N/A | 86,286 | 14% | N/A |
| Diluted EPS (DKK) | 3.79 | (16%) | N/A | 19.45 | 14% | N/A |
| EBITDA | 37,383 | 19% | 15% | 137,902 | 23% | 26% |
| Free cash flow | 28,483 | (13%) | N/A | 83,780 | 18% | N/A |
Cash generation was strong. Free cash flow for the first nine months reached DKK 83.8 billion versus DKK 71.1 billion a year earlier, while capital expenditure on property, plant and equipment was DKK 37.2 billion. Novo returned DKK 61.9 billion to shareholders through dividends of DKK 51.9 billion and share repurchases of DKK 10.0 billion. Net debt stood at DKK 79,725 million at 30 September 2026, compared with DKK 95,424 million at the end of 2025.
Pipeline and Regulatory Milestones Behind Novo Nordisk Q3 2026 Results
CagriSema produced the headline data in the Novo Nordisk Q3 2026 results. At the 1.0/1.0 mg dose, the REDEFINE 9 trial showed 21% weight loss at week 68 in obesity. In the REIMAGINE 5 diabetes trial, the combination delivered 12.4% weight loss against 9.1% for tirzepatide 5 mg at week 60, with non-inferior HbA1c reduction. Novo is preparing a US launch of CagriSema in early 2027, subject to regulatory approval, and has also filed in China.
R&D and Regulatory Milestones Reported in Q3 2026
| Product | Milestone | Key Detail from Report | Expected Timing |
|---|---|---|---|
| Wegovy pill (oral semaglutide 25 mg) | China NDA submitted for obesity | OASIS 4: 16.6% vs 2.7% placebo; 307 adults; 64 weeks | Review completion around turn of 2027/2028 |
| CagriSema 2.4/2.4 mg | China NDA submitted for obesity | Based on REDEFINE programme and regional phase 3a studies | Review completion H1 2028 |
| CagriSema 1.0/1.0 mg | REIMAGINE 5 completed | 12.4% vs 9.1% weight loss vs tirzepatide 5 mg; non-inferior HbA1c at week 60 | US launch early 2027, subject to approval |
| Oral zenagamtide | AMAZE 9 phase 3a initiated | About 950 participants; doses of 6, 12, 25, 50 and 100 mg | Readout H2 2028 |
| Ozempic pill 25 mg | US submission under FDA review | Submitted earlier in 2026 | FDA decision Q4 2026 |
| Frehemgo (denecimig) | Positive CHMP opinion; US BLA review ongoing | Haemophilia A with or without inhibitors; no efficacy or safety deficiencies identified by FDA | EU launches around turn of year; US launch H1 2027, pending approval |
| Ziltivekimab | ZEUS and HERMES missed primary endpoint | DKK 4.6 billion impairment in Q3 | HERMES and ATHENA readouts H1 2027 |
| Semaglutide 2.4 mg (MASH) | Kayshild approved in EU; Wegovy pill MASH submitted to FDA | Wegovy 2.4 mg also approved in UK and Japan for MASH | US timing not disclosed |
| Etavopivat | Phase 3 HIBISCUS completed | Both co-primary endpoints met | Not disclosed |
Full-Year 2026 Guidance, Updated vs Previous
| Guidance Item | 4 November 2026 | 4 August 2026 |
|---|---|---|
| Adjusted sales growth at CER | -2% to +2% | -6% to 0% |
| Adjusted sales growth in DKK | In line with CER growth | Around 1 percentage point lower than CER |
| Adjusted operating profit growth at CER | -2% to +2% | -6% to 0% |
| Adjusted operating profit growth in DKK | In line with CER growth | Around 2 percentage points lower than CER |
| Financial items (net) | Loss of around DKK 1.6 billion | Loss of around DKK 1.1 billion |
| Effective tax rate | 21% to 23% | 21% to 23% |
| Capital expenditure (PP&E) | Around DKK 50 billion | Around DKK 55 billion |
| Free cash flow | DKK 60 to 70 billion | DKK 45 to 55 billion |
